Milestone Scientific Inc. Completes \$2.15 Million Private Placement: Strategic Financing Bolsters Growth Prospects

Key Highlights

• Milestone Scientific Inc. (NYSE: MLSS) has completed a \$2.15 million private placement of common stock and warrants, with the potential for an additional \$2.69 million if cash warrants are fully exercised.
• The financing is designed to strengthen the company’s balance sheet and support its commercial growth strategy, including scaling investments in sales, inventory, and digital marketing.
• Participation from long-term investors and members of the Board, including the CEO, signals strong internal confidence and alignment with the company’s direction.
• The offering was conducted without a placement agent, resulting in no placement or underwriting discounts, commissions, or other fees—a cost-efficient transaction structure.
• Certain directors and officers participated in the offering on the same terms as other investors, purchasing an aggregate of \$150,000 of units for cash, in addition to conversion of bridge notes.
• The private placement was conducted in accordance with NYSE American rules and closed on April 21, 2026.
• Milestone Scientific is a technology-focused medical research and development company specializing in computerized drug delivery instruments for painless and precise injections, with proprietary Dynamic Pressure Sensing Technology®.

Transaction Details

• The company entered into a securities purchase agreement with a group of investors for the private placement of 7,962,963 units at \$0.27 per unit.
• Each unit consists of one share of common stock and one corresponding cash warrant, exercisable at 125% of the purchase price.
• Gross proceeds total \$2.15 million, including \$1.80 million in cash and \$351,000 from conversion of convertible bridge notes previously issued to certain directors and officers.
• No placement agent was used, and no fees were paid—optimizing the proceeds for company operations.
• Directors and officers contributed \$150,000 in cash, plus converted bridge notes, demonstrating alignment and confidence in the company’s future.
• The securities purchase agreement and form of warrant are available in the company’s Current Report on Form 8-K filed with the SEC.

Strategic Implications for Shareholders

• This financing provides Milestone Scientific with the capital necessary to expand commercially, specifically investing in sales, inventory, and digital marketing.
• Participation by the Board and long-term investors is a strong endorsement of the company’s technology and strategy, which could positively impact investor sentiment and share value.
• The cost-efficient structure of the transaction—without placement agent fees—means more funds are available for growth initiatives.
• The conversion of bridge notes by directors and officers aligns management’s interests with shareholders and reduces short-term debt.
• The additional \$2.69 million potential from warrant exercise could further bolster the company’s financial position, subject to investor confidence and share price performance.
• The company’s proprietary DPS Dynamic Pressure Sensing Technology® and its focus on painless, precise injections position it for continued innovation and growth in medical and dental applications.

Forward-Looking Statements and Risks

• The press release contains forward-looking statements regarding Milestone’s ability to execute its business plan, generate expected revenues, timing of regulatory approvals, and future success.
• Risks include general economic conditions, failure to achieve expected revenue growth, changes in operating expenses, adverse patent rulings, regulatory developments, competitive pressures, and changes in customer and market requirements.
• Coding and payment decisions are determined solely by providers and payers, and any potential Category I designation by the American Medical Association is not guaranteed.
• There is no assurance that targeted reimbursement levels or revenue projections will be achieved.

Investor Contacts

• Hayden IR: James Carbonara (646-755-7412, [email protected])
• Brett Maas: (646-536-7331, [email protected])

Disclaimer: This article contains forward-looking statements based on current management beliefs and assumptions. Actual results may differ materially due to various risks and uncertainties. Investors should review all filings with the SEC and consult their financial advisors before making investment decisions. Milestone Scientific Inc. undertakes no obligation to update forward-looking statements. This article is for information purposes only and does not constitute investment advice.

View MILESTONE SCIENTIFIC INC. Historical chart here